T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.16B |
| 2 |
GE Aerospace
GE
|
+$1.93B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.62B |
| 4 |
Eli Lilly
LLY
|
+$1.59B |
| 5 |
SPLK
Splunk Inc
SPLK
|
+$1.38B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$2.72B |
| 2 |
Booking.com
BKNG
|
+$2.61B |
| 3 |
RHT
Red Hat Inc
RHT
|
+$1.62B |
| 4 |
JPMorgan Chase
JPM
|
+$1.43B |
| 5 |
State Street
STT
|
+$1.29B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.46% |
| 2 | Technology | 17.53% |
| 3 | Financials | 14.18% |
| 4 | Consumer Discretionary | 14.02% |
| 5 | Communication Services | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LOMA
726
Loma Negra
LOMA
$1.11B
| $65.1M | 0.01% |
5,851,116
+82,377
| +1% | +$800K |
|
727
Estee Lauder
EL
$31.6B
| $65M | 0.01% |
499,987
+12,290
| +3% | +$1.67M |
|
728
Avient
AVNT
$4.23B
| $65M | 0.01% |
2,271,849
-121,624
| -5% | -$4.07M |
|
729
Omnicom Group
OMC
$24.2B
| $64.6M | 0.01% |
882,058
-107,038
| -11% | -$7.94M |
|
730
NovoCure
NVCR
$2.02B
| $64.5M | 0.01% |
1,926,579
-128,557
| -6% | -$4.7M |
|
|
MLNX
731
DELISTED
Mellanox Technologies, Ltd.
MLNX
| $63.9M | 0.01% |
692,071
+59,318
| +9% | +$5.04M |
|
732
Viatris
VTRS
$18.4B
| $63.8M | 0.01% |
2,327,735
+1,124,919
| +94% | +$36.4M |
|
733
Ingevity
NGVT
$2.59B
| $63.3M | 0.01% |
756,796
+11,492
| +2% | +$1.04M |
|
734
Luxfer Holdings
LXFR
$457M
| $63M | 0.01% |
3,575,852
-220,263
| -6% | -$5M |
|
735
Churchill Downs
CHDN
$6.2B
| $62.9M | 0.01% |
1,548,210
-4,410
| -0.3% | -$195K |
|
736
Charles River Laboratories
CRL
$13.4B
| $62.9M | 0.01% |
555,676
+8,236
| +2% | +$1.03M |
|
737
Five Below
FIVE
$13.4B
| $62.7M | 0.01% |
612,726
-80,225
| -12% | -$8.87M |
|
738
Colliers International
CIGI
$5.41B
| $62.6M | 0.01% |
1,137,065
+151,185
| +15% | +$9.61M |
|
|
MNTA
739
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $62.2M | 0.01% |
5,629,580
+2,617,606
| +87% | +$36.4M |
|
740
Tractor Supply
TSCO
$18.8B
| $62.1M | 0.01% |
3,723,085
-134,700
| -3% | -$2.42M |
|
741
Ionis Pharmaceuticals
IONS
$9.28B
| $62.1M | 0.01% |
1,149,124
+54,588
| +5% | +$2.78M |
|
742
EPAM Systems
EPAM
$5.24B
| $62M | 0.01% |
534,087
+170,298
| +47% | +$20.9M |
|
743
CytomX Therapeutics
CTMX
$730M
| $61.8M | 0.01% |
4,091,526
+3,923
| +0.1% | +$58.2K |
|
744
Dime Commercial Bancshares
DCOM
$1.82B
| $61.7M | 0.01% |
2,420,512
+3,693
| +0.2% | +$108K |
|
745
Atara Biotherapeutics
ATRA
$76.7M
| $61.7M | 0.01% |
71,013
+339
| +0.5% | +$315K |
|
746
Lumentum
LITE
$78B
| $61.5M | 0.01% |
1,463,270
-3,353,321
| -70% | -$165M |
|
|
AEGN
747
DELISTED
Aegion Corp
AEGN
| $61.1M | 0.01% |
3,743,424
+387,798
| +12% | +$7.75M |
|
|
HA
748
DELISTED
Hawaiian Holdings, Inc.
HA
| $61M | 0.01% |
2,309,461
+83,156
| +4% | +$2.81M |
|
|
ACBI
749
DELISTED
Atlantic Capital Bancshares, Inc. Common Stock
ACBI
| $60.6M | 0.01% |
3,702,136
+1,784
| +0% | +$29.4K |
|
750
NetEase
NTES
$78.5B
| $60.6M | 0.01% |
1,286,325
-453,840
| -26% | -$20.5M |
|
Similar funds
T. Rowe Price Associates's Q4 2018 Portfolio in Review
As of Q4 2018, T. Rowe Price Associates held 2,656 positions worth $591B, down 14% from $685B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q4 2018 filing shows 75 new, 1,551 increased, 819 reduced and 97 closed positions. Its largest new stake was StoneCo: 28,883,228 shares worth $519M. The largest sale was Tesla, an estimated $2.72B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Financials.
- T. Rowe Price Associates's largest Q4 2018 buy was StoneCo: 28,883,228 shares worth $519M.
- T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q4 2018, an estimated $2.16B increase.
- T. Rowe Price Associates's biggest Q4 2018 reduction was Tesla, cutting an estimated $2.72B.
- T. Rowe Price Associates fully exited Aetna Inc in Q4 2018, selling an estimated $600M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $591B portfolio in Q4 2018.
- T. Rowe Price Associates opened 75 new positions and closed 97 in Q4 2018.
- T. Rowe Price Associates's portfolio value fell 14% quarter-over-quarter to $591B.
Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.